Anaplastic meningioma
Therapeutic area
Oncology
Rare disease
No
- Definition
- A WHO grade III meningioma characterized by the presence of malignant morphologic features, including malignant cytology and a very high mitotic index (20 or more mitoses per ten high power fields).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Anaplastic meningioma
- Therapeutic area
- Oncology
- anaplastic meningioma
- anaplastic (malignant) meningioma
- anaplastic meningioma
- malignant meningioma
- meningioma, anaplastic, malignant
- Severity
- Severe
- Neurology
- Oncology
- MONDO ID
- MONDO:0020635
- Parent condition
- MONDO:0020633
Related records
Broader conditions (20)
- Anaplastic cancer
- Cancer
- Cancer or benign tumor
- Central nervous system cancer
- Central nervous system disorder
- Central nervous system neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Grade III meningioma
- High grade malignant neoplasm
- Human disease
- Malignant tumor of meninges
- Meningioma
- Neoplasm
- Neoplastic disease or syndrome
- Nervous system cancer
- Nervous system disorder
- Nervous system neoplasm
- Tumor of meninges
Trials (62)
- A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
- A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma
- A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
- A Study of the Safety and Pharmacokinetics (PK) of MEHD7945A in Participants With Locally Advanced or Metastatic Epithelial Tumors
- A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
- A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma
- Allogeneic Stem Cell Transplantation in Pediatric Patients With Malignant and Non-malignant High-risk Diseases
- Antimicrobial Resistance in Acute Cholangitis
- Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in Adults
- Assessment of the Safety and Tolerability of ex Vivo Next-generation Neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) Therapy in Advanced Epithelial Tumors and Immune Checkpoint Blockade (ICB) Resistant Solid Tumors
- Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer
- Brain Connectivity Changes in Glioma Patients During Treatment
- Cellular Immunotherapy Study for Brain Cancer
- CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
- Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tumors
- Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors
- Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced Solid Tumors
- Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor
- Effect of Cabazitaxel on the QTc Interval in Cancer Patients
Drugs in development (2)
- Bevacizumab Phase 2
- Pioglitazone Phase 1